189940-04-3

Basic information

• Product Name: BUTTPARK 120\07-77
• Synonyms: BUTTPARK 120\07-77;6-(TRIFLUOROMETHYL)-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE;3,4-Dihydro-3-oxo-6-(trifluoromethyl)-2H-1,4-benzoxazine, 6-(Trifluoromethyl)-4H-benzo[b][1,4]oxazin-3-one;6-(Trifluoromethyl)-2H-1,4-benzoxazin-3(4H)-one 95%;6-(Trifluoromethyl)-2H-1,4-benzoxazin-3(4H)-one95%;6-(Trifluoromethyl)-2He-1,4-benzoxazin-3(4H)-on;6-(trifluoromethyl)-4H-1,4-benzoxazin-3-one
• CAS NO: 189940-04-3
• Molecular Formula: C₉H₆F₃NO₂
• Molecular Weight: 217.14
• Mol File: 189940-04-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BUTTPARK 120\07-77(CAS DataBase Reference)
• NIST Chemistry Reference: BUTTPARK 120\07-77(189940-04-3)
• EPA Substance Registry System: BUTTPARK 120\07-77(189940-04-3)

Safety Data

• Hazardous Substances Data: 189940-04-3(Hazardous Substances Data)

Upstream product

• 400-99-7 2-nitro-4-trifluoromethylphenol 
• 454-81-9 2-amino-4-(trifluoromethyl)phenol 
• 888731-86-0 2-chloro-N-[2-hydroxy-5-(trifluoromethyl)phenyl]acetamide 

Downstream Products

• 347-40-0 6-trifluoromethyl-3,4-dihydro-2H-benzo[1,4]oxazine 
• 1307845-02-8 C₂₃H₂₂ClF₃N₄O₂ 
• 1307845-01-7 C₂₂H₂₀ClF₃N₄O₂ 
• 1307844-86-5 C₂₁H₁₈ClF₃N₄O₂S 
• 189939-03-5 methyl(E)-2-[2-(6-trifluoromethyl-2H-benzo[1,4]oxazin-3-yloxymethyl)phenyl]-3-methoxypropenoate 

Relevant articles and documents

COMPOUND HAVING 11 ?-HSD1 INHIBITORY ACTIVITY

The present invention provides compounds having excellent 11β-HSD1 inhibitory activity. A compound represented by the following formula (I): [wherein X1 represents an oxygen atom, or the formula -(CR11R12)p-, etc., Y1 represents a hydrogen atom, a hydroxyl group, etc., Z1 represents an oxygen atom or the formula -(NR14)-, R1 represents a hydrogen atom, a halogen atom, a cyano group, a C1-4 alkyl group, a C1-4 alkyl group substituted with 1 to 3 halogen atoms, a C1-4 alkoxy group, a C1-4 alkoxycarbonyl group, a carboxyl group, a carbamoyl group, or an amino group, and m represents an integer of 1 or 2, and R2 represents a hydrogen atom or a C1-4 alkyl group, and n represents an integer of 1 or 2].

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.